<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141580">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01257854</url>
  </required_header>
  <id_info>
    <org_study_id>2009-018105-41</org_study_id>
    <secondary_id>2009-018105-41</secondary_id>
    <nct_id>NCT01257854</nct_id>
  </id_info>
  <brief_title>Polymorphisms and Busulfan Pharmacokinetic Study</brief_title>
  <official_title>Polymorphisms and Busulfan Pharmacokinetic Study in Pediatric Transplnatation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Pediatric Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Group for Blood and Marrow Transplantation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Swiss Pediatric Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Test the correlations between the pharmacogenetic and pharmacokinetic of Busulfan IV in
      children receiving hematopoietic stem cell transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most of the drugs used to treat cancer are metabolized by hepatic enzymes such as cytochrome
      P450 or Glutathion-S-Transferase (GST). These enzymatic pathways can be more or less active
      in the drug's metabolism according to the given polymorphism of each patient
      (pharmacogenomics).

      The current hypothesis is that some functional polymorphisms of genes, which control
      important enzymes in Busulfan metabolism, contribute to the observed interindividual
      variability in PK of this drug. This variability can hence predict the resistance as well as
      the toxicity from a drug in patients who have cancer. The pharmacokinetic profile of
      different drugs, which have a hepatic metabolism, can be dramatically modified by these
      polymorphisms. Busulfan is a major drug used in the conditioning regimen before
      hematopoietic stem cell transplantation, particularly in children in whom total body
      irradiation has to be avoided. This drug has a narrow therapeutic index. At a lower systemic
      exposure than the targeted one, Busulfan has insufficient activity and hence an increased
      risk of transplant rejection and leukemic relapse.

      At higher systemic exposures, the toxicity risk increases dramatically with an elevated
      incidence of hepatic veno-occlusive disease (VOD). Pharmacokinetic monitoring of Busulfan
      allows optimal dosing. The recommended doses are based on the weight, body surface area or
      age. Nevertheless, a majority of patients will still need an adjustment of the dose
      administered after their first dose: this will result in a cumulative systemic exposure that
      will be over or under therapeutic. Busulfan is metabolized principally by the GSTA1, as well
      as by other GST enzymes like the GSTM1 and GSTP1. These enzymes are present in the liver as
      well as in the intestinal cells and are up regulated in the digestive system of young
      children.With this study we will look for the polymorphism in GST genes, look at the
      Busulfan IV pharmacokinetics and finally look at the GST alpha enzyme activity and see if
      there is a correlation with clinical end points. This study will also study any correlation
      with other genes (repair DNA genes, CYP etc..) that could be correlated with Busulfan and/or
      cyclophosphamide. This study will also allow to do some DNA banking for future studies in
      genetics. This multicentric study is sponsor by the Swiss pediatric Oncology Group and is a
      European Bone and Marrow Transplantation study open in 6 countries (Switzerland, Canada,
      Italy, Holland, Tscèque republic, ). Pilot study are first analyze with St. Justine Hospital
      then with the other center at a later stage.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>polymorphisms in genes involved in Busulfan pathways correlation with pharmacokinetic</measure>
    <time_frame>1 year post hematopoietic stem cell transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>polymorphisms in genes involved in Busulfan pathways correlation with toxicity</measure>
    <time_frame>1 year post hematopoietic stem cell transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>polymorphisms in genes involved in Busulfan pathways correlation with survival</measure>
    <time_frame>1 year post stem cell transplantation</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Children Who Receive a Stem Cell Transplantation With Busulfan IV</condition>
  <arm_group>
    <arm_group_label>Busulfan, pharmacogenetic, pharmacokinetic, children</arm_group_label>
    <description>Children who receive Busulfan IV and have a pharmacokinetic of Busulfan</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA from each patient are kept. Plasma from some centers are kept
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        primary care clinic of pediatric
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be ≤ than 18 years of age at study entry on this protocol

          -  The patient must receive iv Busulfan as part of his hematopoietic stem cell
             transplant conditioning regimen.

          -  Each participating center has to go through a PK cross validation

          -  All patients (or their legal guardians) must sign a document of informed consent that
             has been approved by the Institutional Human Review Committee.

          -  Each center has to do his own PK of BU
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ansari Marc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital CAntonal de Genève, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ansari Marc, MD</last_name>
    <phone>+41223824589</phone>
    <email>marc.ansari@hcuge.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Duval Michel, MD</last_name>
    <email>michel.duval@umontreal.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu St Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ansari Marc, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Duval Michel, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Ansari Marc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alberta children's hospital</name>
      <address>
        <city>Alberta</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lewis victor, MD</last_name>
    </contact>
    <investigator>
      <last_name>lewis victor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Rebert de bré</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JH Dalle, PhD</last_name>
      <email>jean-hugues.dalle@rdb.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>JH Dalle, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal de Genève</name>
      <address>
        <city>Geneva</city>
        <zip>1206</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ansari Marc, MD</last_name>
      <phone>+41223824589</phone>
      <email>marc.ansari@hcuge.ch</email>
    </contact>
    <investigator>
      <last_name>Ansari Marc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Krajinovic Maja</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </removed_countries>
  <reference>
    <citation>Ansari M, Lauzon-Joset JF, Vachon MF, Duval M, Théoret Y, Champagne MA, Krajinovic M. Influence of GST gene polymorphisms on busulfan pharmacokinetics in children. Bone Marrow Transplant. 2010 Feb;45(2):261-7. doi: 10.1038/bmt.2009.143. Epub 2009 Jul 6.</citation>
    <PMID>19584821</PMID>
  </reference>
  <reference>
    <citation>Ansari M, Krajinovic M. Can the pharmacogenetics of GST gene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation? Pharmacogenomics. 2009 Nov;10(11):1729-32. doi: 10.2217/pgs.09.135.</citation>
    <PMID>19891548</PMID>
  </reference>
  <results_reference>
    <citation>Ansari M, Rezgui MA, Théoret Y, Uppugunduri CR, Mezziani S, Vachon MF, Desjean C, Rousseau J, Labuda M, Przybyla C, Duval M, Champagne M, Peters C, Bittencourt H, Krajinovic M; Pediatric Disease Working Parties of the European Blood and Marrow Transplant Group.. Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients. Bone Marrow Transplant. 2013 Jul;48(7):939-46. doi: 10.1038/bmt.2012.265. Epub 2013 Jan 7.</citation>
    <PMID>23292236</PMID>
  </results_reference>
  <results_reference>
    <citation>Ansari M, Théoret Y, Rezgui MA, Peters C, Mezziani S, Desjean C, Vachon MF, Champagne MA, Duval M, Krajinovic M, Bittencourt H; Pediatric Disease Working Parties of the European Blood and Marrow Transplant Group.. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation. Ther Drug Monit. 2014 Feb;36(1):93-9. doi: 10.1097/FTD.0b013e3182a04fc7.</citation>
    <PMID>24061446</PMID>
  </results_reference>
  <results_reference>
    <citation>Huezo-Diaz P, Uppugunduri CR, Tyagi AK, Krajinovic M, Ansari M. Pharmacogenetic aspects of drug metabolizing enzymes in busulfan based conditioning prior to allogenic hematopoietic stem cell transplantation in children. Curr Drug Metab. 2014 Mar;15(3):251-64. Review.</citation>
    <PMID>24524663</PMID>
  </results_reference>
  <results_reference>
    <citation>Uppugunduri CR, Rezgui MA, Diaz PH, Tyagi AK, Rousseau J, Daali Y, Duval M, Bittencourt H, Krajinovic M, Ansari M. The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation. Pharmacogenomics J. 2014 Jun;14(3):263-71. doi: 10.1038/tpj.2013.38.</citation>
    <PMID>24165757</PMID>
  </results_reference>
  <results_reference>
    <citation>Acosta-Martin AE, Antinori P, Uppugunduri CR, Daali Y, Ansari M, Scherl A, Müller M, Lescuyer P. Detection of busulfan adducts on proteins. Rapid Commun Mass Spectrom. 2016 Sep 6. doi: 10.1002/rcm.7730. [Epub ahead of print]</citation>
    <PMID>27599297</PMID>
  </results_reference>
  <results_reference>
    <citation>Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, Bredius RG, Egberts AC, Bierings M, Kletzel M, Shaw PJ, Nath CE, Hempel G, Ansari M, Krajinovic M, Théorêt Y, Duval M, Keizer RJ, Bittencourt H, Hassan M, Güngör T, Wynn RF, Veys P, Cuvelier GD, Marktel S, Chiesa R, Cowan MJ, Slatter MA, Stricherz MK, Jennissen C, Long-Boyle JR, Boelens JJ. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016 Nov;3(11):e526-e536. doi: 10.1016/S2352-3026(16)30114-4. Epub 2016 Oct 13.</citation>
    <PMID>27746112</PMID>
  </results_reference>
  <results_reference>
    <citation>Huezo-Diaz Curtis P, Uppugunduri CR, Muthukumaran J, Rezgui MA, Peters C, Bader P, Duval M, Bittencourt H, Krajinovic M, Ansari M. Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation. Pharmacogenomics J. 2016 Oct 25. doi: 10.1038/tpj.2016.65. [Epub ahead of print]</citation>
    <PMID>27779248</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 31, 2017</lastchanged_date>
  <firstreceived_date>December 8, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>busulfan</keyword>
  <keyword>pharmacogenetic</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>toxicity</keyword>
  <keyword>survival</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
